Pharmacological modulation of dopamine receptor D2 mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice

Experimental Diabetes Research 2011; 2011: 928523
Abstract

High fat feeding induces a variety of obese and lean phenotypes in inbred rodents. Compared to Diet Resistant (DR) rodents, Diet Induced Obese (DIO) rodents are insulin resistant and have a reduced dopamine receptor D2 (DRD2) mediated tone. We hypothesized that this differing dopaminergic tone contributes to the distinct metabolic profiles of these animals.

C57Bl6 mice were classified as DIO or DR based on their weight gain during 10 weeks of high fat feeding. Subsequently DIO mice were treated with the DRD2 agonist bromocriptine and DR mice with the DRD2 antagonist haloperidol for 2 weeks.

Compared to DR mice, the body weight of DIO mice was higher and their insulin sensitivity decreased. Haloperidol treatment reduced the voluntary activity and energy expenditure of DR mice and induced insulin resistance in these mice. Conversely, bromocriptine treatment tended to reduce body weight and voluntary activity, and reinforce insulin action in DIO mice.

These results show that DRD2 activation partly redirects high fat diet induced metabolic anomalies in obesity-prone mice. Conversely, blocking DRD2 induces an adverse metabolic profile in mice that are inherently resistant to the deleterious effects of high fat food. This suggests that dopaminergic neurotransmission is involved in the control of metabolic phenotype.
Introduction

Dopamine is intimately involved in the regulation of energy balance. Genetically engineered dopamine-deficient mice fail to initiate feeding and consequently die of starvation, unless L-DOPA, the precursor of dopamine, is provided daily\(^1\). Conversely, dopamine release in response to food intake induces satiety and reward\(^2\). Thus, dopamine plays an important dual role in the complex physiology driving meal initiation and termination. Moreover, dopaminergic neurotransmission profoundly affects glucose and lipid metabolism\(^3\).

Dopamine action is mediated by 5 distinct G-protein coupled receptor subtypes, functionally classified into 2 receptor families according to their effect on target neurons. Activation of dopamine receptor D2 (DRD2), D3 or D4, comprising the D2 family, inhibits adenylyl cyclase. Activation of the receptors belonging to the D1 family (DRD1 and DRD5) stimulates adenylyl cyclase\(^4\).

Dopaminergic transmission is altered in insulin resistant and obese animals. Basal and feeding evoked dopamine release is exaggerated in several nuclei of the hypothalamus of obese Zucker rats\(^5-7\), whereas DRD2 expression is reduced in hypothalamic nuclei of obese animal models\(^8,9\). The number of DRD2 binding sites in the striatum of obese humans is reduced and inversely correlated with body mass index\(^10\).

Modulation of DRD2 activity profoundly affects energy homeostasis in humans and animals. Drugs that block DRD2 enhance appetite and induce weight gain in animals and humans\(^11-14\). Conversely, DRD2 agonist drugs reduce body weight, increase energy expenditure and improve glycemic control in obese animals and individuals\(^15-18\).

High fat feeding induces obesity, insulin resistance and diabetes in rodents. However, the amount of weight gained in response to a high fat diet varies considerably, even among animals with a genetically identical background\(^19-21\). Indeed, diet sensitive (diet induced obese, DIO) rodents display several alterations in pathways regulating energy homeostasis compared to diet resistant (DR) rodents\(^21,22\), and DIO and DR rodents differ with respect to various components of their dopaminergic system, even before the onset of obesity\(^23,24\). In particular, DIO mice and rats are characterized by an increased expression of dopamine transporter and reduced DRD2 expression\(^23\). In view of the evidence summarized above, altered DRD2 mediated neurotransmission could contribute to the metabolic phenotype of these animals. We hypothesized that modulation of dopaminergic transmission in DIO and DR mice with DRD2 agonist or antagonist drugs would redirect the metabolic phenotypes of these mice. We particularly postulated that stimulation of DRD2 would ameliorate insulin resistance of DIO C57Bl6 mice, whereas DRD2 antagonism would induce insulin resistance in DR animals of the same strain. To address this hypothesis, DIO and DR mice were treated with bromocriptine, a DRD2 agonist, or
Material and Methods

Animals
Seventy-two male C57BL/6J mice (Charles River, Maastricht, The Netherlands), 11 or 12 weeks old, were housed in a temperature- and humidity-controlled room on a 12-h light–dark cycle with free access to food and water, unless mentioned otherwise.

All animal experiments were performed in accordance with the principles of laboratory animal care and regulations of Dutch law on animal welfare, and the experimental protocol was approved by the Animal Ethics Committee of the Leiden University Medical Center.

Experimental design
All mice were maintained on a high fat diet (45 energy% of fat derived from palm oil, 35 energy% of carbohydrate and 20 energy% of protein; Research Diet Services, Wijk bij Duurstede, The Netherlands). After 10 weeks of high fat feeding, the 24 mice with the highest weight gain were classified as DIO mice and the 24 mice with the lowest weight gain were classified as DR mice. The 24 mice with intermediate weight gain were not further used in this study.

DIO and DR mice were randomly divided into a placebo and treatment group. DR treated mice received haloperidol (1 mg/kg/day), DIO treated mice received bromocriptine (10 mg/kg/day) and DIO and DR placebo mice received placebo treatment. Subcutaneous implantable haloperidol, bromocriptine and placebo pellets (Innovative Research of America, Florida, USA), ensuring continuous release of the medication were used. Pellets were implanted under isoflurane anesthesia. Mice were treated for 2 weeks, meanwhile maintained on the high fat diet.

Measurement of energy metabolism
Mice were subjected to indirect calorimetric measurements for a period of 3 consecutive days using a Comprehensive Laboratory Animal Monitoring System (CLAMS; Columbus Instruments, Ohio, USA). Due to a limited number of cages, eight mice per group were measured. Mice were allowed to acclimatize to the cages for a period of 14 hours prior to the start of the experiment. Measurements started at 7.00 am and continued for 72 hours. The CLAMS system enables real-time continuous monitoring of food intake, drinking behavior, activity...
and metabolic gas exchange. Oxygen consumption (VO₂) and carbon dioxide production rates (VCO₂) were measured at 7 minute intervals. The respiratory exchange rate (RER), as a measure for metabolic substrate choice, was calculated using the following formula:

\[ RER = \frac{VCO_2}{VO_2} \]

Carbohydrate and fat oxidation rates were calculated from VO₂ and VCO₂ using the following formulas:\(^{25}\):

- Carbohydrate oxidation (kcal/h) = \((4.585 \times VCO_2) - (3.226 \times VO_2)\) \times 4/1000
- Fat oxidation (kcal/h) = \((1.695 \times VO_2) - (1.701 \times VCO_2)\) \times 9/1000

VO₂ and VCO₂ are in ml/h.

Total energy expenditure was calculated as the sum of carbohydrate and fat oxidation. Activity was monitored by infrared beam breaks across the x- and y-axis. All energy metabolism data was calculated separately for day and night time.

**DEXAscan**

Body composition was measured by dual-energy X-ray absorptiometry (DEXA) using the Norland pDEXA Sabre X-Ray Bone Densitometer (Norland, Hampshire, UK). Before measuring, mice were anesthetized with a combination of 6.25 mg/kg acepromazine (Alfasan, Woerden, The Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands) and 0.3125 mg/kg fentanyl (Janssen-Cilag, Tilburg, The Netherlands).

**Hyperinsulinemic euglycemic clamp**

Prior to the experiment, mice were fasted for 16 hours after food withdrawal at 5.00 pm. Hyperinsulinemic euglycemic clamp studies started at 9.00 am and were performed as described earlier\(^{26}\). During the experiment, mice were anesthetized with a combination of 6.25 mg/kg acepromazine (Alfasan, Woerden, The Netherlands), 6.25 mg/kg midazolam (Roche, Mijdrecht, The Netherlands) and 0.3125 mg/kg fentanyl (Janssen-Cilag, Tilburg, The Netherlands). First, the basal rate of glycerol turnover was determined by giving a primed (0.6 μCi) continuous (0.9 μCi/h) intravenous (i.v.) infusion of \([1-(3)-3^H]\)-Glycerol (GE Healthcare, Little Chalfont, UK) for 60 minutes. Subsequently, insulin (Novo Nordisk, Bagsværd, Denmark) was administered in a primed (4.5 mU) continuous (6.8 mU/h) i.v. infusion for 90 minutes to attain a steady state circulating insulin concentration of ~6 μg/l.

Every 10 min the plasma glucose concentration was determined via tail vein bleeding (< 3 µl) (Accu-chek, Sensor Comfort, Roche Diagnostics GmbH, Mannheim, Germany) and accordingly the i.v. infusion rate of a 12.5% D-glucose solution was adjusted to maintain euglycemia. Blood samples (60 µl) were taken during the basal period (at 50 and 60 min) and during the hyperinsulinemic period (at 70, 80, and 90 min) to determine plasma concentrations of glucose,
insulin, Non-Esterified Fatty Acids (NEFA), free glycerol and \( ^3 \text{H} \)-Glycerol specific activities. At the end of the clamp mice were sacrificed.

**Analytical procedures**

Commercially available kits were used to determine the plasma concentration of glucose (Instruchemie, Delfzijl, The Netherlands), NEFA (Wako, Nuess, Germany) and free glycerol (Sigma, MO, USA). The plasma insulin concentration was measured by an ELISA (Mercodia AB, Uppsala, Sweden). Total plasma \( ^3 \text{H} \)-Glycerol was determined in plasma and in supernatant after trichloroacetic acid (20%) precipitation and water evaporation.

**Calculations**

The turnover rate of glycerol (\( \mu \text{mol/min/kg} \)) was calculated during the basal period and under steady-state hyperinsulinemic conditions as the rate of tracer infusion (dpm/min) divided by the plasma-specific activity of \( ^3 \text{H} \)-Glycerol (dpm/\( \mu \text{mol} \)). The turnover rates were corrected for body weight.

**Statistical analysis**

Data is presented as mean ± standard deviation. Statistical analysis was performed using SPSS. A one-way ANOVA was used for analysis of the data. If significant differences were found, the LSD method was applied as post-hoc test to determine differences between 2 groups. Statistical differences are only shown when apparent between DIO and DR placebo groups, between DIO placebo and bromocriptine groups or between DR placebo and haloperidol groups. Differences were considered statistically significant when \( p<0.05 \).

**Results**

**Body weight and basal plasma metabolites**

Mice were designated DIO or DR according to their weight gain following a 10-week high fat diet. By definition, DIO mice had a significantly higher body weight compared to DR mice after this dietary pre-treatment (35.4±1.5 vs. 30.6±1.9; \( p<0.001 \)), which was completely accounted for by a difference in fat mass (fig 1B). Lean body mass did not differ (not shown). Two weeks of placebo treatment did not alter the difference in body weight between DIO and DR mice (fig 1A). Two weeks of bromocriptine treatment tended to induce weight loss in DIO mice (primarily fat mass, fig 1B), although the effect did not reach statistical significance. Haloperidol did not impact on the body weight of DR mice.

The fasting plasma glucose concentration was not different between placebo treated DIO and DR mice (fig 2A), whereas the fasting plasma insulin concentration was significantly elevated in DIO mice (fig 2B). Haloperidol significantly increased fasting plasma glucose and insulin concentrations in DR mice, while the insulin and glucose concentrations in DIO mice remained
unchanged upon bromocriptine treatment. The fasting plasma NEFA concentration didn’t differ between the groups (fig 2C).

Figure 1 - Body weight (A) and fat mass (B) of DIO and DR mice after treatment with bromocriptine (BC), haloperidol (HP) or placebo (P) for 2 weeks. Data is presented as mean ± SD for 12 (A) or 10 (B) mice per group.

** p<0.01, *** p<0.001

Figure 2 - Fasting plasma glucose (A), insulin (B) and NEFA (C) concentrations in DIO and DR mice after treatment with bromocriptine (BC), haloperidol (HP) or placebo (P) for 2 weeks. Data is presented as mean ± SD for 9 or 10 mice per group.

* p<0.05, ** p<0.01
Energy metabolism

After 1 week of treatment, whole body energy metabolism of mice was assessed with a Comprehensive Laboratory Animal Monitoring System using indirect calorimetry. Individual food intake, activity and respiratory gas exchange was monitored for 3 consecutive days. Cumulative food intake (fig 3A), voluntary activity (fig 3B,C), energy expenditure (fig 3D) as well as the carbohydrate oxidation rate (data not shown) did not differ between placebo treated DIO and DR mice. The diurnal fat oxidation rate tended to be higher in DIO mice, but this failed to reach statistical significance (fig 3E). Diurnal and nocturnal voluntary

Figure 3 - Cumulative food intake (A), mean nocturnal (B) and diurnal x-axis activity (C), mean nocturnal energy expenditure (D) and mean diurnal fat oxidation rate (E) in DIO and DR mice after treatment with bromocriptine (BC), haloperidol (HP) or placebo (P) for 1 week. Data is presented as mean ± SD for 7 or 8 mice per group.

** p<0.01, *** p<0.001
activity in DR mice was dramatically reduced by haloperidol (fig 3B,C), and this was accompanied by a reduction in whole body nocturnal energy expenditure (fig 3D). The impact of haloperidol on fat (fig 3E) and carbohydrate oxidation (data not shown) did not reach statistical significance. Food intake was not affected by haloperidol treatment (fig 3A). The diurnal voluntary activity tended to be lower in DIO mice receiving bromocriptine, but this also failed to reach statistical significance (fig 3C). Furthermore, bromocriptine treatment had no significant effect on food intake (fig 3A), energy expenditure (fig 3D), fat oxidation (fig 3E) or carbohydrate oxidation (data not shown).

**Insulin action**

After 2 weeks of treatment, mice were subjected to a hyperinsulinemic euglycemic clamp. Basal and hyperinsulinemic plasma glucose, insulin, free glycerol and NEFA concentrations are shown in table 1. The plasma NEFA concentration was reduced to the same extent in all groups during hyperinsulinemia.

The glucose infusion rate necessary to maintain euglycemia was significantly higher in DR compared to DIO mice (fig 4), which indicates that DIO mice were insulin resistant compared to DR animals. Haloperidol significantly diminished the glucose infusion rate in DR mice, reflecting a deterioration of insulin action, whereas bromocriptine tended to increase glucose infusion required to maintain euglycemia in DIO mice (indicating improved insulin action). The capacity of insulin to inhibit glycerol turnover was not different between DR and DIO mice and it was not affected by either drug (data not shown).

**Table 1** - Plasma glucose, insulin, free glycerol and NEFA concentrations during the basal and hyperinsulinemic conditions of the hyperinsulinemic euglycemic clamp in DIO and DR mice after treatment with bromocriptine, haloperidol or placebo for 2 weeks.

| Clamp condition | DIO mice                | DR mice                |
|----------------|-------------------------|------------------------|
|                | Placebo | Bromocriptine | Placebo | Haloperidol |
| Glucose (mM)   |          |              |          |             |
| B              | 5.9 ± 0.6 | 5.3 ± 1.1    | 5.0 ± 0.6 | 6.7 ± 1.7   |
| HI             | 5.4 ± 0.7 | 5.6 ± 0.6    | 6.0 ± 0.7 | 4.8 ± 1.1   |
| Insulin (μg/l) |          |              |          |             |
| B              | 2.4 ± 0.3 | 2.0 ± 0.8    | 1.6 ± 0.5 | 2.6 ± 0.7   |
| HI             | 6.8 ± 1.9 | 7.2 ± 1.4    | 6.7 ± 1.3 | 7.1 ± 0.6   |
| Free Glycerol (mM) |          |              |          |             |
| B              | 0.1 ± 0.1 | 0.1 ± 0.1    | 0.2 ± 0.1 | 0.2 ± 0.1   |
| HI             | 0.1 ± 0.0 | 0.1 ± 0.0    | 0.1 ± 0.0 | 0.1 ± 0.0   |
| NEFA (mM)      |          |              |          |             |
| B              | 1.0 ± 0.2 | 1.1 ± 0.3    | 1.1 ± 0.2 | 1.0 ± 0.3   |
| HI             | 0.5 ± 0.1 | 0.5 ± 0.1    | 0.5 ± 0.2 | 0.5 ± 0.1   |

B, Basal; HI, Hyperinsulinemia

Data is measured in 9 or 10 mice per group and presented as mean ± SD.
Discussion

The results presented here demonstrate that pharmacological modulation of dopaminergic transmission by a DRD2 agonist or antagonist can partly redirect the divergent metabolic phenotypes of DIO and DR mice. In particular, blocking dopaminergic transmission by means of haloperidol induces insulin resistance of glucose metabolism in DR mice. Conversely, activation of dopaminergic neurotransmission by bromocriptine tends to ameliorate insulin resistance in DIO animals. These data suggest that DRD2 mediated neurotransmission is involved in the control of glucose and insulin metabolism.

Although they have a genetically identical background, individual C57Bl6 mice show distinct susceptibility to develop obesity and insulin resistance when maintained on a high fat diet. We classified mice as DIO or DR based on the amount of weight gained during 10 weeks of high fat feeding. DIO mice were insulin resistant compared to DR mice, as evidenced by higher fasting plasma insulin levels and a lower glucose infusion rate required to maintain euglycemia during insulin infusion. These findings are in accordance with other rodent studies\textsuperscript{19-21,24,27}. Remarkably, there was no measurable difference in food intake, energy expenditure or voluntary physical activity in DIO compared to DR mice.

DIO mice have significantly lower DRD2 expression levels in certain brain areas compared to DR mice\textsuperscript{23}. Also, dopamine turnover is reduced in hypothalamic nuclei of DIO rats even before the onset of obesity\textsuperscript{24} and the hypothalamus is intimately involved in the control of glucose and lipid metabolism\textsuperscript{28,29}. Since pharmacological activation of DRD2 ameliorates insulin resistance in various obese animal models\textsuperscript{17,30}, we hypothesized that modulation of DRD2 mediated neurotransmission could reverse the metabolic phenotypes of DIO and DR mice. In keeping with this hypothesis, blocking DRD2 by haloperidol induced insulin resistance in DR mice, whereas activation of DRD2 by bromocriptine tended to improve insulin sensitivity in DIO mice. In concert, these data suggest that DRD2 activation is involved in the control of glucose metabolism and that reduced dopaminergic transmission via DRD2 contributes to the metabolic
phenotype (insulin resistance) of obese animals.

However, we cannot exclude the possibility that the observed effects of bromocriptine and haloperidol are (partly) mediated by receptors other than DRD2. Haloperidol is also known to have a high affinity for DRD3, DRD4 and adrenergic α1 receptors\(^\text{31}\) and bromocriptine also possesses high affinity for DRD3, the serotonergic 5-HT1A and 1D receptors and the adrenergic α1 and α2 receptors\(^\text{32}\). Each of these receptors might participate in the impact of haloperidol and/or bromocriptine on energy and nutrient homeostasis. Adrenergic receptors (AR) are involved in the control of energy expenditure and glucose metabolism. Stimulation of α2-AR reduces spontaneous physical activity\(^\text{33}\) and impairs insulin secretion\(^\text{34-36}\). Accordingly, overexpression of α2A-AR is associated with glucose intolerance\(^\text{37}\). Stimulation of α1-AR, on the other hand, has a positive impact on glucose homeostasis by promoting glucose uptake by adipose and muscle tissue\(^\text{38-40}\) and absence of the α1B-AR leads to hyperinsulinemia and insulin resistance\(^\text{41}\). Acute stimulation of the 5-HT1A receptor increases food intake\(^\text{42,43}\), reduces plasma insulin levels and induces a concomitant rise in plasma glucose levels\(^\text{44,45}\). As far as we know, the specific impact of DRD3, DRD4 and 5-HT1D receptors on the regulation of energy and nutrient homeostasis is still unknown. Thus, the effects of bromocriptine and haloperidol we observe here may be the ultimate result of modulation of various of these receptor activities.

The fact that haloperidol induced insulin resistance is consistent with literature reporting an increased incidence of diabetes among individuals treated with haloperidol\(^\text{46}\). Interestingly, treatment with haloperidol is not associated with (massive) weight gain in humans\(^\text{47}\), which also fits with our data and suggests that the drug hampers insulin action via mechanistic routes other than obesity. First, haloperidol dramatically reduced physical activity of DR mice. This is in agreement with a wealth of data from other animal experiments\(^\text{48,49}\). Diminished locomotor activity hampers insulin action in muscle\(^\text{50,51}\). Second, a major (side) effect of haloperidol treatment is elevation of prolactin levels\(^\text{52,53}\) which may contribute to the induction of glucose intolerance and insulin resistance\(^\text{54,55}\). Third, haloperidol may alter glucose metabolism by modifying plasma levels of peptide hormones. The data documenting effects of haloperidol on leptin levels are inconsistent; increased\(^\text{56}\) as well as unchanged leptin levels in response to haloperidol treatment have been reported\(^\text{57,58}\). But, haloperidol seems to increase plasma ghrelin levels, while leaving levels of adiponectin, resistin and visfatin unaffected\(^\text{56}\). Both leptin and ghrelin may impact on insulin sensitivity directly\(^\text{59,60}\). Fourth, haloperidol may diminish glucose induced insulin secretion by blocking D2 receptors on pancreatic β-cells\(^\text{61,62}\), which leads to (postprandial) hyperglycemia. In the long run, hyperglycemia diminishes insulin action through “toxic” effects on insulin sensitive tissues\(^\text{63}\). Fifth, blockade of central DRD2 may induce insulin resistance via modulation
of autonomic nervous output to peripheral tissues (including muscle, adipose tissue and liver).\textsuperscript{64}

Bromocriptine treatment tended to improve insulin sensitivity of glucose metabolism in DIO animals, but its effect on glucose infusion rate did not reach statistical significance. It is important to note that the route of bromocriptine administration we used here may have diminished the efficacy of the drug. Indeed, it has been shown that subcutaneous, compared to intraperitoneal, administration of the drug limits its metabolic impact.\textsuperscript{65} The tendency we observed though, is in line with data obtained in diet induced obese hamsters\textsuperscript{66}, and genetically engineered obese mice\textsuperscript{67}. In accordance, short term administration of bromocriptine ameliorates various metabolic anomalies in obese humans without affecting body weight\textsuperscript{18} and longer term treatment improves glycemic control and serum lipid profiles in patients with type 2 diabetes.\textsuperscript{68} In addition, DRD2 agonists improve glucose and lipid metabolism in patients with hyperprolactinemia\textsuperscript{69,70} and acromegaly\textsuperscript{71-73}. Although DRD2 agonists generally benefit nutrient metabolism, the use of these drugs is sometimes associated with the development of impulse control disorders, including binge and compulsive eating, in patients with Parkinson's disease, which may lead to excessive weight gain and insulin resistance.\textsuperscript{74,75}

The effects of bromocriptine on metabolism may be mediated by central dopamine receptors, as is suggested by Luo et al.\textsuperscript{17} who showed that intracerebroventricular administration of low dose bromocriptine during 14 days improves insulin sensitivity in obese, insulin resistant, hamsters. However, peripheral receptors might also be involved. We previously reported that bromocriptine acutely impairs insulin secretion by stimulating the α2-AR on β-cells.\textsuperscript{36} To explain that (sub)chronic bromocriptine treatment improves glucose metabolism\textsuperscript{15,66,76}, we hypothesized that suppression of insulin secretion induces β-cell ‘rest’, which might allow β-cells to replenish insulin stores, thereby enhancing the secretory capacity in the long run.\textsuperscript{77,78} It might also increase the number of organ specific insulin receptors leading to improved insulin sensitivity.\textsuperscript{79,80} In addition, bromocriptine may alter glucose metabolism via modulation of circulating peptide levels. In obese women bromocriptine reduces leptin concentrations\textsuperscript{81}; the biological relevance of this for the results reported by us is questionable however, as leptin improves insulin sensitivity.\textsuperscript{59}

The impact of bromocriptine on other regulatory peptide hormones remains to be determined.

In summary, activation of DRD2 tends to ameliorate the metabolic profile of DIO mice, whereas antagonism of these receptors induces insulin resistance in DR mice. In concert with previous findings by other groups indicating that dopaminergic (DRD2 mediated) neurotransmission is reduced in the brain of DIO mice, our data suggest that DRD2 mediated dopaminergic mechanisms may be involved in the development of the divergent metabolic phenotypes in response to high fat feeding in C57Bl6 mice.
Acknowledgements

The research described in this paper is supported by the Dutch Diabetes Foundation (project 2002.01.005), the Nutrigenomics Consortium/Top Institute Food and Nutrition (NGC/TIFN) and the Centre of Medical Systems Biology (CMSB) established by The Netherlands Genomics Initiative/Netherlands Organization for Scientific Research (NGI/NWO).

References

1. Zhou QY and Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. *Cell* 1995; 83: 1197-1209
2. Meguid MM, Fetissov SO, Varma M, Sato T, Zhang L, Laviano A and Rossi-Fanelli F. Hypothalamic dopamine and serotonin in the regulation of food intake. *Nutrition* 2000; 16: 843-857
3. Meier AH and Cincotta AH. Circadian Rhythms regulate the expression of the thrifty genotype/phenotype. *Diabetes Reviews* 1996; 4: 464-487
4. Nestler EJ. Hard target: understanding dopaminergic neurotransmission. *Cell* 1994; 79: 923-926
5. Yang ZJ and Meguid MM. LHA dopaminergic activity in obese and lean Zucker rats. *Neuroreport* 1995; 6: 1191-1194
6. Lemierre S, Rouch C, Nicolaidis S and Orosco M. Combined effect of obesity and aging on feeding-induced monoamine release in the rostromedial hypothalamus of the Zucker rat. *Int J Obes Relat Metab Disord* 1998; 22: 993-999
7. Orosco M, Rouch C, Meile MJ and Nicolaidis S. Spontaneous feeding-related monoamine changes in rostromedial hypothalamus of the obese Zucker rat: a microdialysis study. *Physiol Behav* 1995; 57: 1103-1106
8. Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a “thrifty” genotype underlying the metabolic syndrome? *Eur J Pharmacol* 2003; 480: 125-131
9. Fetissov SO, Meguid MM, Sato T and Zhang LH. Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. *Am J Physiol Regul Integr Comp Physiol* 2002; 283: R905-R910
10. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N and Fowler JS. Brain dopamine and obesity. *Lancet* 2001; 357: 354-357
11. Baptista T, Araujo de Baptista E, Ying Kin NM, Beaulieu S, Walker D, Joober R, Lalonde J and Richard D. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. *Brain Res* 2002; 957: 144-151
12. Baptista T, Parada M and Hernandez L. Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? *Pharmacol Biochem Behav* 1987; 27: 399-405
13. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. *CNS Drugs* 2005; 19 Suppl 1: 1-93
14. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M and Bergman RN. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. *Diabetes* 2005; 54: 862-871

15. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH and DeFronzo RA. Bromocriptine: a novel approach to the treatment of type 2 diabetes. *Diabetes Care* 2000; 23: 1154-1161

16. Kuo DY. Co-administration of dopamine D1 and D2 agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats. *J Biomed Sci* 2002; 9: 126-132

17. Luo S, Liang Y and Cincotta AH. Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters. *Neuroendocrinology* 1999; 69: 160-166

18. Kok P, Roelfsema F, Frolich M, van Pelt J, Stokkel MP, Meinders AE and Pijl H. Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women. *Am J Physiol Endocrinol Metab* 2006; 291: E1038-E1043

19. Chang S, Graham B, Yakubu F, Lin D, Peters JC and Hill JO. Metabolic differences between obesity-prone and obesity-resistant rats. *Am J Physiol* 1990; 259: R1103-R1110

20. Burcelin R, Crivelli V, DaCosta A, Roy-Tirelli A and Thorens B. Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet. *Am J Physiol Endocrinol Metab* 2002; 282: E834-E842

21. Huang XF, Han M and Storlien LH. The level of NPY receptor mRNA expression in diet-induced obese and resistant mice. *Brain Res Mol Brain Res* 2003; 115: 21-28

22. Clegg DJ, Benoit SC, Reed JA, Woods SC, Dunn-Meynell A and Levin BE. Reduced anorexic effects of insulin in obesity-prone rats fed a moderate-fat diet. *Am J Physiol Regul Integr Comp Physiol* 2005; 288: R981-R986

23. Huang XF, Zavitsanou K, Huang X, Yu Y, Wang H, Chen F, Lawrence AJ and Deng C. Dopamine transporter and D2 receptor binding densities in mice prone or resistant to chronic high fat diet-induced obesity. *Behav Brain Res* 2006; 175: 415-419

24. Levin BE and Dunn-Meynell AA. Dysregulation of arcuate nucleus prepro neuropeptide Y mRNA in diet-induced obese rats. *Am J Physiol* 1997; 272: R1365-R1370

25. McLean JA, Tobin G. Animal and human calorimetry. Cambridge: Cambridge University Press, 1987.

26. Voshol PJ, Jong MC, Dahlmans VE, Kratky D, Levak-Frank S, Zechnier R, Romijn JA and Havekes LM. In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake. *Diabetes* 2001; 50: 2585-2590

27. Leibowitz KL, Chang GQ, Pamy PS, Hill JO, Gayles EC and Leibowitz SF. Weight gain model in prepubertal rats: prediction and phenotyping of obesity-prone animals at normal body weight. *Int J Obes* 2007; 31: 1210-1221

28. van den Hoek AM, Voshol PJ, Karnekamp BN, Buijs RM, Romijn JA, Havekes LM and Pijl H. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. *Diabetes* 2004; 53: 2529-2534
29. Pocai A, Lam TK, Gutierrez-Juarez R, Obici S, Schwartz GJ, Bryan J, Aguilar-Bryan L and Rossetti L. Hypothalamic K(ATP) channels control hepatic glucose production. *Nature* 2005; 434: 1026-1031

30. Cincotta AH, Tozzo E and Scislowski PW. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. *Life Sci* 1997; 61: 951-956

31. Schmidt AW, Lebel LA, Howard HR, Jr. and Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. *Eur J Pharmacol* 2001; 425: 197-201

32. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA and Newman-Tancredi A. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. *J Pharmacol Exp Ther* 2002; 303: 791-804

33. Lahdesmaki J, Sallinen J, MacDonald E, Sirvio J and Scheinin M. Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype. *Neuropharmacology* 2003; 44: 882-892

34. Ostenson CG, Cattaneo AG, Doxey JC and Efendic S. Alpha-adrenoceptors and insulin release from pancreatic islets of normal and diabetic rats. *Am J Physiol* 1989; 257: E439-E443

35. Peterhoff M, Sieg A, Brede M, Chao CM, Hein L and Ullrich S. Inhibition of insulin secretion via distinct signaling pathways in alpha2-adrenoceptor knockout mice. *Eur J Endocrinol* 2003; 149: 343-350

36. de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, Pijl H and Guigas B. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. *Biochem Pharmacol* 2010; 79: 1827-1836

37. Devedjian JC, Pujol A, Cayla C, George M, Casellas A, Paris H and Bosch F. Transgenic mice overexpressing alpha2A-adrenoceptors in pancreatic beta-cells show altered regulation of glucose homeostasis. *Diabetologia* 2000; 43: 899-906

38. Hutchinson DS and Bengtsson T. alpha1A-adrenoceptors activate glucose uptake in L6 muscle cells through a phospholipase C-, phosphatidylinositol-3 kinase-, and atypical protein kinase C-dependent pathway. *Endocrinology* 2005; 146: 901-912

39. Faintrenie G and Geloen A. Alpha-1 adrenergic stimulation of glucose uptake in rat white adipocytes. *J Pharmacol Exp Ther* 1998; 286: 607-610

40. Flechtner-Mors M, Jenkinson CP, Alt A, Biesalski HK, Adler G and Ditschuneit HH. Sympathetic regulation of glucose uptake by the alpha1-adrenoceptor in human obesity. *Obes Res* 2004; 12: 612-620

41. Burcelin R, Uldry M, Foretz M, Perrin C, DaCosta A, Neniger-Tosato M, Seydoux J, Cotecchia S and Thorens B. Impaired glucose homeostasis in mice lacking the alpha1b-adrenergic receptor subtype. *J Biol Chem* 2004; 279: 1108-1115

42. Hutson PH, Dourish CT and Curzon G. Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT1A receptors. *Eur J Pharmacol* 1988; 150: 361-366

43. Lam DD and Heisler LK. Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes. *Expert Rev Mol Med* 2007; 9: 1-24
44. Chaouloff F and Jeanrenaud B. 5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n-propylamino) tetralin in the conscious rat. *J Pharmacol Exp Ther* 1987; 243: 1159-1166

45. Uvnas-Moberg K, Ahlenius S, Alster P and Hillegaart V. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat. *Neuroendocrinology* 1996; 63: 269-274

46. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A and Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. *J Clin Epidemiol* 2003; 56: 164-170

47. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC and Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. *Am J Psychiatry* 1999; 156: 1686-1696

48. Simon VM, Parra A, Minarro J, Arenas MC, Vinader-Caerols C and Aguilar MA. Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. *Eur Neuropsychopharmacol* 2000; 10: 159-164

49. Wiley JL and Evans RL. Evaluation of age and sex differences in locomotion and catalepsy during repeated administration of haloperidol and clozapine in adolescent and adult rats. *Pharmacol Res* 2008; 58: 240-246

50. Stuart CA, Shangraw RE, Prince MJ, Peters EJ and Wolfe RR. Bed-rest-induced insulin resistance occurs primarily in muscle. *Metabolism* 1988; 37: 802-806

51. Alibegovic AC, Hojbjerre L, Sonne MP, van Hall G, Stalknecht B, Dela F and Vaag A. Impact of 9 days of bed rest on hepatic and peripheral insulin action, insulin secretion, and whole-body lipolysis in healthy young male offspring of patients with type 2 diabetes. *Diabetes* 2009; 58: 2749-2756

52. Hruska RE. Modulatory role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonists. *Brain Res Bull* 1986; 16: 331-339

53. Xu R, Parlow AF and Wang Y. The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor. *Brain Res* 2002; 939: 95-99

54. Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC and Kim HJ. Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. *J Clin Endocrinol Metab* 1980; 51: 242-246

55. Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bahcec M and Tuzcu S. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. *Pituitary* 2009; 12: 330-334

56. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, Pelayo-Teran JM, Carrasco-Marin E, Mata I and Crespo-Facorro B. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. *J Clin Psychopharmacol* 2008; 28: 289-295

57. Kraus T, Haack M, Schulz A, Hinze-Selch D, Kuhn M, Uhr M and Pollmacher T. Body weight and leptin plasma levels during treatment with antipsychotic drugs. *Am J Psychiatry* 1999; 156: 312-314
58. von Wilmsdorff M, Bouvier ML, Henning U, Schmitt A and Gaebel W. The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats. *Clinics (Sao Paulo)* 2010; 65: 885-894
59. van den Hoek AM, Teusink B, Voshol PJ, Havekes LM, Romijn JA and Pijl H. Leptin deficiency per se dictates body composition and insulin action in ob/ob mice. *J Neuroendocrinol* 2008; 20: 120-127
60. Heijboer AC, van den Hoek AM, Parlevliet ET, Havekes LM, Romijn JA, Pijl H and Corssmit EP. Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice. *Diabetologia* 2006; 49: 732-738
61. Melkersson K, Khan A, Hilding A and Hulting AL. Different effects of antipsychotic drugs on insulin release in vitro. *Eur Neuropsychopharmacol* 2001; 11: 327-332
62. Garcia-Tornadu I, Ornstein AM, Chamson-Reig A, Wheeler MB, Hill DJ, Arany E, Rubinstein M and Becu-Villalobos D. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. *Endocrinology* 2010; 151: 1441-1450
63. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. *Ann Intern Med* 1996; 124: 97-103
64. Carey RM, Van Loon GR, Baines AD and Kaiser DL. Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man. *J Clin Endocrinol Metab* 1983; 56: 595-602
65. Durant S, Coulaud J and Homo-Delarche F. Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action. *Rev Diabet Stud* 2007; 4: 185-194
66. Luo S, Meier AH and Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. *Neuroendocrinology* 1998; 68: 1-10
67. Scisłowski PW, Tozzo E, Zhang Y, Phaneuf S, Prevelige R and Cincotta AH. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. *Int J Obes Relat Metab Disord* 1999; 23: 425-431
68. Cincotta AH, Meier AH and Cincotta JM. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. *Expert Opin Investig Drugs* 1999; 8: 1683-1707
69. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G and Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. *Eur J Endocrinol* 2003; 149: 187-193
70. Dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC and Gadelha MR. BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists. *Obesity (Silver Spring)* 2011; 19: 800-805
71. Chiba T, Chihara K, Minamitani N, Goto B, Kadowaki S, Taminato T, Matsukura S and Fujita T. Effect of long term bromocriptine treatment on glucose intolerance in acromegaly. *Horm Metab Res* 1982; 14: 57-61
72. Hainer V, Zak A, Sindelkova E, Wernischova V, Belikova H and Skorepa J. Elevation of high density lipoproteins in acromegalics after lisuride treatment. *Horm Metab Res* 1985; 17: 220-221
73. Rau H, Althoff PH, Schmidt K, Badenhoop K and Usadel KH. Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion. *Clin Investig* 1993; 71: 372-378
74. Nirenberg MJ and Waters C. Compulsive eating and weight gain related to dopamine agonist use. *Mov Disord* 2006; 21: 524-529
75. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR and Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. *Arch Neurol* 2010; 67: 589-595
76. Cincotta AH and Meier AH. Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). *Metabolism* 1995; 44: 1349-1355
77. Song SH, Rhodes CJ, Veldhuis JD and Butler PC. Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. *Endocrinology* 2003; 144: 3399-3405
78. Leahy JL, Bumbalo LM and Chen C. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. *Diabetes* 1994; 43: 173-179
79. Alemzadeh R, Slonim AE, Zdanowicz MM and Maturo J. Modification of insulin resistance by diazoxide in obese Zucker rats. *Endocrinology* 1993; 133: 705-712
80. Alemzadeh R and Holshouser S. Effect of diazoxide on brain capillary insulin receptor binding and food intake in hyperphagic obese Zucker rats. *Endocrinology* 1999; 140: 3197-3202
81. Kok P, Roelfsema F, Frolich M, van PJ, Meinders AE and Pijl H. Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women. *J Clin Endocrinol Metab* 2006; 91: 3236-3240